Senate Bill 164
117th Congress(2021-2022)
Advancing Education on Biosimilars Act of 2021
Became Law
Became Public Law 117-8 on Apr 23, 2021
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
164
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
checkPassed on March 3, 2021
Status
Passed
Type
Unanimous Consent
Unanimous Consent
A senator may request unanimous consent on the floor to set aside a specified rule of procedure so as to expedite proceedings. If no Senator objects, the Senate permits the action, but if any one senator objects, the request is rejected. Unanimous consent requests with only immediate effects are routinely granted, but ones affecting the floor schedule, the conditions of considering a bill or other business, or the rights of other senators, are normally not offered, or a floor leader will object to it, until all senators concerned have had an opportunity to inform the leaders that they find it acceptable.
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)
Summary
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
Sort by most recent
04/23/2021
Became Public Law No: 117-8.
04/23/2021
Signed by President.
04/20/2021
Presented to President.
04/14/2021
Motion to reconsider laid on the table Agreed to without objection.
04/14/2021
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754)
04/14/2021
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101).(text: CR H1754)
04/14/2021
Considered as unfinished business. (consideration: CR H1783-1784)
04/14/2021
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
04/14/2021
DEBATE - The House proceeded with forty minutes of debate on S. 164.
04/14/2021
Considered under suspension of the rules. (consideration: CR H1754-1755)
04/14/2021
Mr. Pallone moved to suspend the rules and pass the bill.
03/08/2021
Held at the desk.
03/08/2021
Received in the House.
03/08/2021
Message on Senate action sent to the House.
03/03/2021
Passed Senate without amendment by Unanimous Consent. (text: CR S1021)
03/03/2021
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)
03/03/2021
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021)
03/03/2021
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021)
02/02/2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
02/02/2021
Introduced in Senate
Public Record
Record Updated
Jan 11, 2023 1:46:42 PM